Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

By David M. Brown, M. Michels, P. Kaiser, J. Heier, J. P. Sy, T. Ianchulev. Ophthalmology (Rochester, Minn.), 2009

1,448 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/d1fb6b1dbaa72cf394f2d5de21c4d9dcebe1ef1a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Adamis
2. N. Ferrara

In Ophthalmology

1. N. Ferrara
2. A. Adamis

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, methodology): “Ranibizumab was approved for the treatment of AMD in 2006, following the success of the Phase III (ANCHOR) 208,209 and MARINA 207 trials, which showed that ranibizumab not only reduced vision loss but also improved visual acuity.”